 The FDA has a bevy of safety concerns surrounding Verves gene-editing approach to high cholesterol, leading VERV stock to dive Monday. The post Verve Therapeutics Stock Skids On The FDAs Long List Of Gene-Editing Concerns appeared first on Investors Business Daily. 